Parabilis Medicines is pioneering stabilized, cell-penetrant α-helical peptides, called Helicons™, to modulate intracellular proteins that small molecules and antibodies cannot reach. Its lead candidate, FOG-001 (zolucatetide), directly inhibits the β-catenin:TCF interaction within the Wnt/β-catenin pathway and has shown meaningful single-agent activity across five tumor types, including desmoid tumors and adamantinomatous craniopharyngioma. The drug has U.S. FDA Fast Track Designation for desmoid tumors and is moving toward a registrational trial while additional data in hepatocellular carcinoma and familial adenomatous polyposis are forthcoming. Beyond FOG-001, Parabilis is advancing preclinical Helicon degraders against ERG and allosteric ARON for prostate cancer, demonstrating the broad applicability of its platform. Headquartered in Cambridge, Massachusetts, the company leverages proprietary data, AI- and physics-based algorithms, and more than a decade of laboratory innovation. Financially, Parabilis closed an oversubscribed $305 million Series F round at an increased valuation, positioning it to expand clinical and preclinical programs. No revenue or user metrics have been disclosed, consistent with its clinical-stage status.

Total raised

$305M

Funding rounds

1

Latest round

Series F

Latest activity

Jan 2026